title: Time to response in generalized anxiety disorder in a naturalistic setting: combination therapy with alprazolam orally disintegrating tablets and serotonin reuptake inhibitors compared to serotonin reuptake inhibitors alone.
abstract: OBJECTIVE
  This study investigated the therapeutic potential of initiating treatment of generalized anxiety disorder (GAD) with alprazolam orally disintegrating tablets (ODT) in combination with an SSRI or SNRI, compared with SSRI/SNRI monotherapy.
  
  
  METHODS
  Subjects were randomized to eight weeks open-label treatment with alprazolam ODT (4 weeks treatment followed by a 3- to 4-week taper) combined with an SSRI or SNRI, or treatment with SSRI/SNRI alone.
  
  
  METHODS
  The study was conducted at 43 primary care and 22 psychiatric practices under naturalistic conditions.
  
  
  METHODS
  Subjects ≥ 18 years of age with a primary diagnosis of GAD.
  
  
  METHODS
  The primary efficacy measure was time to response, a ≥50-percent decrease from baseline in Hamilton Rating Scale for Anxiety (HAM-A) total score. Secondary variables included HAM-A total and sub-factor scores, and the Clinical Global Impression of Improvement (CGI-I) and Patient Global Impression (PGI) scales.
  
  
  RESULTS
  The intent-to-treat population included 129 subjects. Discontinuation due to adverse events occurred in one subject in each group. There was no statistical difference between groups in the primary efficacy variable of time to response on the HAM-A. Combination treatment with alprazolam ODT and SSRI/SNRI was associated with statistically significant advantages on prespecified secondary variables including earlier improvement in the HAM-A total score and insomnia item and responses on the CGI-I and PGI scales.
  
  
  CONCLUSIONS
  Combination treatment did not differ from monotherapy on time to response but was associated with more rapid improvement in insomnia and global secondary measures.
authors.affiliation: Dr. Rapaport is from the Department of Psychiatry, Cedars-Sinai Medical Center, and from the Department of Psychiatry and Behavioral Neurosciences, David Geffen School of Medicine and Biobehavioral Sciences at UCLA, Los Angeles, California.
authors.forename: Mark Hyman
authors.initials: MH
authors.lastname: Rapaport
authors.forename: Steve B
authors.initials: SB
authors.lastname: Skarky
authors.forename: David J
authors.initials: DJ
authors.lastname: Katzelnick
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Dewester
authors.forename: James M
authors.initials: JM
authors.lastname: Harper
authors.forename: Kay E
authors.initials: KE
authors.lastname: McCrary